EUSA Pharma wins accelerated approval for rare cancer drug

9 May 2017

UK-based specialty pharmaceutical company EUSA Pharma has received European approval for the immunotherapy dinutuximab beta, as a treatment for high-risk neuroblastoma patients over the age of one.

The rare cancer, which predominantly affects children under five, is the second most common solid tumor in childhood. Every year in Europe, around 1,200 children are diagnosed.

Dinutuximab beta, an antibody that has been investigated in clinical trials involving over 1,000 patients, has orphan drug designation in the USA and EU.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK